Streetbeat News

Price Targets

SWN

Mizuho analyst Nitin Kumar has downgraded Southwestern Energy (NYSE:SWN) from Neutral to Underperform and reduced the price target from $9 to $6.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:46 pm

OXY

Mizuho analyst Nitin Kumar downgraded Occidental Petroleum (NYSE:OXY) from Buy to Neutral and set a price target of $63. The downgrade reflects a more cautious stance on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:44 pm

COCP

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Cocrystal Pharma (NASDAQ:COCP) but has reduced the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:43 pm

XOM

Mizuho analyst Nitin Kumar downgraded Exxon Mobil (NYSE:XOM) from Buy to Neutral and set a price target of $117.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:42 pm

MBLY

Raymond James analyst Brian Gesuale has downgraded Mobileye Global (MBLY) from Strong Buy to Outperform, also reducing the price target from $50 to $48.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:39 pm

AVXL

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Anavex Life Sciences (NASDAQ:AVXL) but reduced the price target from $54 to $40.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:33 pm

CIVI

Mizuho analyst Nitin Kumar has upgraded Civitas Resources (NYSE:CIVI) from Neutral to Buy and set a price target of $86.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:25 pm

DPZ

Barclays analyst Jeffrey Bernstein has maintained an Underweight rating on Domino's Pizza (NYSE:DPZ) but increased the price target from $340 to $346.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:10 pm

PTVE

Citigroup analyst Anthony Pettinari has upgraded Pactiv Evergreen (PTVE) from Neutral to Buy and increased the price target from $10 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:07 pm

HCAT

Evercore ISI Group analyst Elizabeth Anderson upgraded Health Catalyst (HCAT) from In-Line to Outperform and increased the price target from $9 to $11.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:06 pm